Logo image of NUVB

NUVATION BIO INC (NUVB) Stock Fundamental Analysis

NYSE:NUVB - US67080N1019 - Common Stock

2.9 USD
+0.16 (+5.84%)
Last: 8/22/2025, 8:27:45 PM
2.9 USD
0 (0%)
After Hours: 8/22/2025, 8:27:45 PM
Fundamental Rating

2

Taking everything into account, NUVB scores 2 out of 10 in our fundamental rating. NUVB was compared to 193 industry peers in the Pharmaceuticals industry. NUVB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. NUVB is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

NUVB had negative earnings in the past year.
In the past year NUVB has reported a negative cash flow from operations.
In the past 5 years NUVB always reported negative net income.
In the past 5 years NUVB always reported negative operating cash flow.
NUVB Yearly Net Income VS EBIT VS OCF VS FCFNUVB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M -400M -500M

1.2 Ratios

NUVB has a Return On Assets (-31.35%) which is in line with its industry peers.
NUVB's Return On Equity of -54.41% is in line compared to the rest of the industry. NUVB outperforms 52.85% of its industry peers.
Industry RankSector Rank
ROA -31.35%
ROE -54.41%
ROIC N/A
ROA(3y)-44.25%
ROA(5y)-34.58%
ROE(3y)-50.3%
ROE(5y)-38.48%
ROIC(3y)N/A
ROIC(5y)N/A
NUVB Yearly ROA, ROE, ROICNUVB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400

1.3 Margins

NUVB has a Gross Margin (27.54%) which is in line with its industry peers.
NUVB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 27.54%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NUVB Yearly Profit, Operating, Gross MarginsNUVB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

4

2. Health

2.1 Basic Checks

NUVB does not have a ROIC to compare to the WACC, probably because it is not profitable.
NUVB has more shares outstanding than it did 1 year ago.
NUVB has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, NUVB has a worse debt to assets ratio.
NUVB Yearly Shares OutstandingNUVB Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
NUVB Yearly Total Debt VS Total AssetsNUVB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

NUVB has an Altman-Z score of -0.13. This is a bad value and indicates that NUVB is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -0.13, NUVB perfoms like the industry average, outperforming 51.81% of the companies in the same industry.
A Debt/Equity ratio of 0.13 indicates that NUVB is not too dependend on debt financing.
NUVB's Debt to Equity ratio of 0.13 is in line compared to the rest of the industry. NUVB outperforms 49.74% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF N/A
Altman-Z -0.13
ROIC/WACCN/A
WACC10%
NUVB Yearly LT Debt VS Equity VS FCFNUVB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 9.39 indicates that NUVB has no problem at all paying its short term obligations.
The Current ratio of NUVB (9.39) is better than 81.35% of its industry peers.
A Quick Ratio of 9.38 indicates that NUVB has no problem at all paying its short term obligations.
NUVB has a Quick ratio of 9.38. This is amongst the best in the industry. NUVB outperforms 81.87% of its industry peers.
Industry RankSector Rank
Current Ratio 9.39
Quick Ratio 9.38
NUVB Yearly Current Assets VS Current LiabilitesNUVB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

NUVB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -70.27%.
The Revenue has grown by 900.35% in the past year. This is a very strong growth!
EPS 1Y (TTM)-70.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.33%
Revenue 1Y (TTM)900.35%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%236.79%

3.2 Future

Based on estimates for the next years, NUVB will show a very strong growth in Earnings Per Share. The EPS will grow by 53.75% on average per year.
NUVB is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 198.08% yearly.
EPS Next Y-27.07%
EPS Next 2Y-1.21%
EPS Next 3Y6.57%
EPS Next 5Y53.75%
Revenue Next Year1439.72%
Revenue Next 2Y741.7%
Revenue Next 3Y383.16%
Revenue Next 5Y198.08%

3.3 Evolution

NUVB Yearly Revenue VS EstimatesNUVB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
NUVB Yearly EPS VS EstimatesNUVB Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 -2 3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NUVB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NUVB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NUVB Price Earnings VS Forward Price EarningsNUVB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NUVB Per share dataNUVB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.21%
EPS Next 3Y6.57%

More info and screens

0

5. Dividend

5.1 Amount

NUVB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NUVATION BIO INC

NYSE:NUVB (8/22/2025, 8:27:45 PM)

After market: 2.9 0 (0%)

2.9

+0.16 (+5.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)11-04 2025-11-04/amc
Inst Owners62.3%
Inst Owner Change12.04%
Ins Owners18.01%
Ins Owner Change0.82%
Market Cap995.48M
Analysts84.62
Price Target7.65 (163.79%)
Short Float %25.43%
Short Ratio10.58
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)0.89%
Min EPS beat(2)0.88%
Max EPS beat(2)0.9%
EPS beat(4)2
Avg EPS beat(4)-4.48%
Min EPS beat(4)-13.12%
Max EPS beat(4)0.9%
EPS beat(8)5
Avg EPS beat(8)-9.69%
EPS beat(12)9
Avg EPS beat(12)-1.98%
EPS beat(16)11
Avg EPS beat(16)-0.69%
Revenue beat(2)2
Avg Revenue beat(2)926.18%
Min Revenue beat(2)625.64%
Max Revenue beat(2)1226.72%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.65%
PT rev (3m)-4.25%
EPS NQ rev (1m)0.6%
EPS NQ rev (3m)0.1%
EPS NY rev (1m)2.54%
EPS NY rev (3m)2.96%
Revenue NQ rev (1m)123.76%
Revenue NQ rev (3m)363.21%
Revenue NY rev (1m)117.73%
Revenue NY rev (3m)121.63%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 69.35
P/FCF N/A
P/OCF N/A
P/B 2.67
P/tB 2.76
EV/EBITDA N/A
EPS(TTM)-0.63
EYN/A
EPS(NY)-0.53
Fwd EYN/A
FCF(TTM)-0.49
FCFYN/A
OCF(TTM)-0.49
OCFYN/A
SpS0.04
BVpS1.09
TBVpS1.05
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -31.35%
ROE -54.41%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 27.54%
FCFM N/A
ROA(3y)-44.25%
ROA(5y)-34.58%
ROE(3y)-50.3%
ROE(5y)-38.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 37.06%
Cap/Sales 2.7%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.39
Quick Ratio 9.38
Altman-Z -0.13
F-Score4
WACC10%
ROIC/WACCN/A
Cap/Depr(3y)79.93%
Cap/Depr(5y)109.07%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-70.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.33%
EPS Next Y-27.07%
EPS Next 2Y-1.21%
EPS Next 3Y6.57%
EPS Next 5Y53.75%
Revenue 1Y (TTM)900.35%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%236.79%
Revenue Next Year1439.72%
Revenue Next 2Y741.7%
Revenue Next 3Y383.16%
Revenue Next 5Y198.08%
EBIT growth 1Y-99.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-107.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-107.44%
OCF growth 3YN/A
OCF growth 5YN/A